Lv1
10 积分 2023-07-24 加入
Phase II Study (NO LIMIT, WJOG13320G) of First-Line Nivolumab Plus Low-Dose Ipilimumab for Microsatellite Instability–High Advanced Gastric or Esophagogastric Junction Cancer
27天前
已完结
First-line cadonilimab plus chemotherapy in HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma: a randomized, double-blind, phase 3 trial
27天前
已完结
Emerging trends in the global burden of colorectal cancer
27天前
已完结
Nivolumab plus chemotherapy as first-line treatment for advanced gastric, gastroesophageal junction, and esophageal adenocarcinoma: 5-year follow-up results from CheckMate 649
28天前
已完结
Efficacy of adjuvant fluorouracil and folinic acid in colon cancer
1个月前
已完结
Current research status and challenges of neoadjuvant immunotherapy for Esophageal squamous cell carcinoma
1个月前
已完结
Adjuvant treatment for esophageal cancer
1个月前
已完结
Neoadjuvant immunotherapy for resectable esophageal cancer: Research progress and clinical perspectives
1个月前
已完结
Adjuvant treatment for esophageal cancer
1个月前
已完结
Harnessing biomarkers to guide immunotherapy in esophageal cancer: toward precision oncology
1个月前
已完结
皖公网安备34019202002308
